| Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens W Jiang, RK Gupta, MC Deshpande, SP Schwendeman Advanced drug delivery reviews 57 (3), 391-410, 2005 | 623 | 2005 |
| Stabilization and controlled release of bovine serum albumin encapsulated in poly (D, L-lactide) and poly (ethylene glycol) microsphere blends W Jiang, SP Schwendeman Pharmaceutical research 18, 878-885, 2001 | 255 | 2001 |
| In vitro and in vivo characterizations of PEGylated liposomal doxorubicin W Jiang, R Lionberger, LX Yu Bioanalysis 3 (3), 333-344, 2011 | 119 | 2011 |
| Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial MD Privitera, TE Welty, BE Gidal, FJ Diaz, R Krebill, JP Szaflarski, ... The Lancet Neurology 15 (4), 365-372, 2016 | 108 | 2016 |
| Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers SP Schwendeman, G Zhu, H Bentz, JA Hubbell, W Jiang, A Shenderova, ... US Patent 6,743,446, 2004 | 107 | 2004 |
| Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: establishing baseline values AD Leino, EC King, W Jiang, AA Vinks, J Klawitter, U Christians, ... American Journal of Transplantation 19 (5), 1410-1420, 2019 | 95 | 2019 |
| The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation W Jiang, S Kim, X Zhang, RA Lionberger, BM Davit, DP Conner, ... International journal of pharmaceutics 418 (2), 151-160, 2011 | 95 | 2011 |
| Generic lamotrigine versus brand‐name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard TY Ting, W Jiang, R Lionberger, J Wong, JW Jones, MA Kane, ... Epilepsia 56 (9), 1415-1424, 2015 | 93 | 2015 |
| Novel bioequivalence approach for narrow therapeutic index drugs LX Yu, W Jiang, X Zhang, R Lionberger, F Makhlouf, DJ Schuirmann, ... Clinical Pharmacology & Therapeutics 97 (3), 286-291, 2015 | 90 | 2015 |
| Equivalence of complex drug products: advances in and challenges for current regulatory frameworks L Hussaarts, S Mühlebach, VP Shah, S McNeil, G Borchard, B Flühmann, ... Annals of the New York Academy of Sciences 1407 (1), 39-49, 2017 | 82 | 2017 |
| Stabilization of tetanus toxoid encapsulated in PLGA microspheres W Jiang, SP Schwendeman Molecular pharmaceutics 5 (5), 808-817, 2008 | 76 | 2008 |
| Stabilization of a model formalinized protein antigen encapsulated in poly (lactide‐co‐glycolide)‐based microspheres W Jiang, SP Schwendeman Journal of pharmaceutical sciences 90 (10), 1558-1569, 2001 | 72 | 2001 |
| The effect of excipients on the permeability of BCS Class III compounds and implications for biowaivers A Parr, IJ Hidalgo, C Bode, W Brown, M Yazdanian, MA Gonzalez, ... Pharmaceutical research 33, 167-176, 2016 | 70 | 2016 |
| Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach RG Greenberg, C Melloni, H Wu, D Gonzalez, L Ku, KD Hill, CP Hornik, ... Clinical neuropharmacology 39 (5), 232-240, 2016 | 69 | 2016 |
| Effect of common excipients on the oral drug absorption of biopharmaceutics classification system class 3 drugs cimetidine and acyclovir S Vaithianathan, SH Haidar, X Zhang, W Jiang, C Avon, TC Dowling, ... Journal of pharmaceutical sciences 105 (2), 996-1005, 2016 | 65 | 2016 |
| A bioequivalence approach for generic narrow therapeutic index drugs: evaluation of the reference-scaled approach and variability comparison criterion W Jiang, F Makhlouf, DJ Schuirmann, X Zhang, N Zheng, D Conner, ... The AAPS journal 17, 891-901, 2015 | 56 | 2015 |
| Formaldehyde‐mediated aggregation of protein antigens: Comparison of untreated and formalinized model antigens W Jiang, SP Schwendeman Biotechnology and bioengineering 70 (5), 507-517, 2000 | 55 | 2000 |
| Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial M Berg, TE Welty, BE Gidal, FJ Diaz, R Krebill, JP Szaflarski, ... Jama Neurology 74 (8), 919-926, 2017 | 53 | 2017 |
| Challenges and opportunities in the development of complex generic long-acting injectable drug products MN O'Brien, W Jiang, Y Wang, DM Loffredo Journal of controlled release 336, 144-158, 2021 | 52 | 2021 |
| Scientific and regulatory considerations for generic complex drug products containing nanomaterials N Zheng, DD Sun, P Zou, W Jiang The AAPS journal 19, 619-631, 2017 | 50 | 2017 |
